Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 28, 2004; DOI: 10.1124/jpet.104.070375
0022-3565/04/3111-99-108$20.00
JPET 311:99-108, 2004
CELLULAR AND MOLECULAR
Insulin Signaling Regulates
-Glutamylcysteine Ligase Catalytic Subunit Expression in Primary Cultured Rat Hepatocytes
Sang K. Kim1,
Kimberley J. Woodcroft,
Sarah S. Khodadadeh, and
Raymond F. Novak
Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan
Decreased glutathione (GSH) levels and
-glutamylcysteine ligase (GCL) activity have been observed in diabetic patients, and insulin reportedly increases GSH synthesis via increased GCL catalytic subunit (GCLC) gene expression. The signaling pathways responsible for mediating insulin effects on GCLC expression and GSH levels, however, are unknown. The signaling pathways involved in the regulation of GSH synthesis in response to insulin were examined in primary cultured rat hepatocytes. GSH levels, GCL activity, GCLC protein, and mRNA levels were increased to 140, 160, 600, and 340% of that monitored in untreated cells, respectively, in hepatocytes cultured with 100 nM insulin. The phosphatidylinositol 3-kinase (PI3K) inhibitors, wortmannin and LY294002 [2-(4-morpholinyl)-9-phenyl-4H-1-benzopyran-4-one], dominant-negative Akt, or rapamycin, an inhibitor of mTOR (mammalian target of rapamycin) and ribosomal p70 S6 kinase (p70S6K) phosphorylation, inhibited the insulin-mediated increase in GCLC protein and GSH levels. Although the mitogen-activated protein kinases (MAPKs) extracellular signal-regulated kinase, p38 MAPK, and JNK (c-Jun N-terminal kinase) were activated in response to insulin, PD98059 (2'-amino-3'-methoxyflavone), an inhibitor of mitogen-activated protein kinase kinase, SP600125 (1,9-pyrazoloanthrone), an inhibitor of JNK, and SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole], an inhibitor of p38 MAPK, failed to inhibit the insulin-mediated increase in GCLC protein levels. In conclusion, these data show that insulin signaling pathways involving PI3K/Akt/p70S6K, but not MAPKs, are active in the insulin-mediated regulation of GSH synthesis via increased GCLC expression.
Received for publication
April 20, 2004
Accepted
May 27, 2004.
Address correspondence to: Dr. Raymond F. Novak, National Institute of Environmental Health Sciences, Wayne State University, 2727 Second Avenue, Room 4000, Detroit, MI 48201. E-mail: r.novak{at}wayne.edu
This article has been cited by other articles:

|
 |

|
 |
 
M. J. Farquhar, H. J. Harris, M. Diskar, S. Jones, C. J. Mee, S. U. Nielsen, C. L. Brimacombe, S. Molina, G. L. Toms, P. Maurel, et al.
Protein Kinase A-Dependent Step(s) in Hepatitis C Virus Entry and Infectivity
J. Virol.,
September 1, 2008;
82(17):
8797 - 8811.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Kim, M. A. Abdelmegeed, and R. F. Novak
THE MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) INHIBITOR PD98059 ELEVATES PRIMARY CULTURED RAT HEPATOCYTE GLUTATHIONE LEVELS INDEPENDENT OF INHIBITING MEK
Drug Metab. Dispos.,
April 1, 2006;
34(4):
683 - 689.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Kim, M. A. Abdelmegeed, and R. F. Novak
Identification of the Insulin Signaling Cascade in the Regulation of Alpha-Class Glutathione S-Transferase Expression in Primary Cultured Rat Hepatocytes
J. Pharmacol. Exp. Ther.,
March 1, 2006;
316(3):
1255 - 1261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Ramos, C. Fernandez, D. Amran, P. Sancho, E. de Blas, and P. Aller
Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells
Blood,
May 15, 2005;
105(10):
4013 - 4020.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.